What is the difference between white bagging and brown bagging?

Both route the drug through a payer's specialty pharmacy under the pharmacy benefit rather than through provider purchasing. The difference is delivery. Under white bagging the specialty pharmacy ships the patient-specific dose to the provider's site. Under brown bagging it dispenses the drug to the patient, who transports it to the appointment. Brown bagging carries greater chain-of-custody and storage concerns because the product is outside professional control between dispense and administration.

Is white bagging allowed under 340B?

White bagging is not prohibited by the 340B statute, but it generally does not generate 340B savings. Savings under 340B arise when the covered entity purchases the drug at the 340B price. Under a typical white bagging arrangement the payer's specialty pharmacy purchases and dispenses the drug, so it does not run through the covered entity's 340B account. Specifics depend on how the individual arrangement is structured and on applicable HRSA guidance.

Can a payer require white bagging?

It depends on the payer, the plan type, and the state. A number of states have enacted laws limiting or prohibiting payer-mandated white bagging, and the scope of those laws differs by state. Whether a state law applies to self-funded employer plans is a separate question. Providers should review their current contract language and their own state's statutes, and involve counsel where the answer is unclear.

How does white bagging change infusion billing?

Under buy and bill, the provider submits a medical benefit claim for both the drug HCPCS code and the administration codes. Under white bagging, the drug is billed by the dispensing specialty pharmacy under the pharmacy benefit, and the provider bills only the administration codes. Drug revenue and drug margin move off the provider's claim entirely, while receiving, storage, and scheduling coordination work typically remain with the provider.

Buy and Bill vs White Bagging vs Brown Bagging

Buy and bill, white bagging, and brown bagging compared: who bears the risk in each, how payer mandates are reshaping the choice, and what it means for 340B.

Every provider-administered drug reaches the patient's chair through one of three channels: buy and bill, white bagging, or brown bagging. For decades the choice was not really a choice. Providers bought the drug, stocked it, administered it, and billed the payer under the medical benefit. That is buy and bill. Now payers are steering volume toward their own contracted specialty pharmacies, and the acquisition channel has become a contracting decision with real margin, workflow, and patient-safety consequences.

For 340B covered entities the stakes are higher. The channel determines whether the drug ever touches your 340B purchasing account at all.

Key Takeaways

Buy and bill means the provider purchases, stores, administers, and bills for the drug. It carries inventory and reimbursement risk - and of these three channels it is generally the only one in which the covered entity purchases the drug, and therefore generally the only one that can produce 340B savings. Arrangements where the entity's own pharmacy supplies the dose are a separate case.
White bagging shifts purchasing to a payer-designated specialty pharmacy. The provider bills administration only, and the drug margin goes away.
Brown bagging puts the drug in the patient's hands before the appointment. ASHP has published policy positions opposing brown bagging of provider-administered medications on chain-of-custody grounds - read its current positions directly before setting organizational policy.
Payer mandates, not provider preference, are driving most of the shift. Several states have enacted restrictions on payer-mandated white bagging, but the rules vary considerably and you should check your own state law.
Drugs supplied by a payer's specialty pharmacy under white bagging are generally not purchased by the covered entity and therefore generally do not produce 340B savings.

What is buy and bill?

Buy and bill is the traditional acquisition model for medical benefit drugs. The practice or health center purchases the medication through its own wholesaler account, holds it in inventory, administers it to the patient, and then bills the payer under the medical benefit for both the drug and the administration. The provider fronts the acquisition cost and carries the financial risk until the claim adjudicates and pays.

Because the drug moves through the provider's own purchasing account, buy and bill is the only one of the three channels in which a 340B covered entity can acquire the medication at the 340B price.

The reimbursement mechanics matter. Medicare Part B generally pays separately payable drugs at the average sales price plus 6 percent under Section 1847A of the Social Security Act, and the statutory sequester reduces the effective payment below that. Commercial payers typically benchmark to ASP or AWP with a negotiated multiplier that is set in the contract, not by the market.

ASP + 6%

Statutory Medicare Part B payment rate for separately payable drugs, before sequestration

Source: Social Security Act Section 1847A / CMS

Medicare sequestration reduction that lowers effective Part B drug payment below the statutory rate

Source: CMS, Budget Control Act sequestration

9-0

Supreme Court vote in American Hospital Association v. Becerra (2022) rejecting Medicare's reduced OPPS rate for 340B drugs. It governs hospital outpatient payment and does not change FQHC PPS reimbursement

Source: American Hospital Association v. Becerra, 596 U.S. 724 (2022)

What is white bagging?

White bagging is when a payer's contracted specialty pharmacy dispenses a patient-specific dose and ships it directly to the provider's site for administration. The provider never purchases the drug and does not bill for it. The drug adjudicates under the pharmacy benefit, and the provider bills only the administration codes.

The definition is tidier than the operations. The dose arrives labeled for one patient and one appointment. If the visit reschedules, that dose is stranded. If lab results change the dose, the shipped product may no longer match the order. If the shipment is late, the patient goes home untreated.

The workflow cost is usually underestimated. White bagging moves drug cost off your books, but it moves scheduling coordination, receiving, patient-specific storage, and reconciliation onto your staff - unreimbursed. Model the labor before you model the margin.

What is brown bagging?

Brown bagging is when a specialty pharmacy dispenses the drug directly to the patient, who transports it to the appointment and hands it to clinical staff for administration. The provider has no visibility into how the product was stored or handled between dispense and administration. As with white bagging, the drug is billed under the pharmacy benefit and the provider bills administration only.

Chain of custody is the central concern. ASHP has published policy positions opposing brown bagging of provider-administered medications and urging caution on payer-mandated white bagging, citing risks around cold-chain integrity, product tampering, storage conditions, and the inability to verify a product before it enters a patient. State boards of pharmacy have raised parallel concerns about who holds professional responsibility for a product the pharmacy no longer controls and the provider never owned. These are the positions of those bodies, and they are worth reading directly before your organization sets policy.

Buy and bill vs. white bagging vs. brown bagging

The three channels differ in who purchases the drug, how it is reimbursed, and who controls it before administration. White bagging and brown bagging both route the drug through a payer's specialty pharmacy under the pharmacy benefit. The difference is delivery: under white bagging the specialty pharmacy ships the patient-specific dose to the provider's site, and under brown bagging it dispenses the drug to the patient, who transports it to the appointment.

	Buy and bill	White bagging	Brown bagging
Who purchases	The provider, through its own wholesaler account	Payer's contracted specialty pharmacy	Payer's contracted specialty pharmacy
Who holds inventory	Provider holds general stock and manages par levels	Specialty pharmacy ships patient-specific dose to the site	Patient holds the product until the appointment
Reimbursement mechanism	Medical benefit; provider bills drug plus administration	Pharmacy benefit for the drug; provider bills administration only	Pharmacy benefit for the drug; provider bills administration only
Margin implications	Spread between acquisition cost and contracted rate, offset by carrying cost, waste, and denial risk	No drug margin; administration revenue only, against added coordination labor	No drug margin; administration revenue only, against added handling risk
Clinical and chain-of-custody risk	Provider controls sourcing, storage, and verification end to end	Product arrives from outside the provider's control; dose changes and reschedules create waste and delay	Highest exposure - storage and transport occur entirely outside professional control
340B eligibility impact	Eligible for 340B pricing when the entity purchases the drug and the patient meets the 340B patient definition	Generally no 340B savings, because the covered entity does not purchase the drug	Generally no 340B savings, for the same reason

Who actually bears the risk

Buy and bill concentrates financial risk with the provider. You pay for the drug before you are paid for it. A denied claim, a missed prior authorization, an expired vial, or a wasted partial dose is your loss. Programs that run buy and bill well run it with tight prior authorization discipline, accurate waste documentation, and reconciliation between what was dispensed and what was billed. Programs that do not discover the gap in an audit.

White and brown bagging remove that financial exposure and replace it with operational and clinical exposure. You no longer carry the drug cost. You also no longer control whether the right drug, at the right dose, in the right condition, is in the building when the patient arrives. And you lose the drug margin that, in most infusion programs, helps fund the nursing, pharmacy, and scheduling infrastructure the service line runs on.

That last point is the one leadership teams miss. Administration reimbursement alone rarely sustains an infusion suite. If the acquisition channel changes and the cost structure does not, the program's economics change with it.

Site of care optimization and what payers are actually optimizing

Payers describe these mandates as site of care optimization: steering infusions toward the lowest-cost setting and the lowest-cost acquisition channel. Allowed amounts for the same infusion can differ substantially between a hospital outpatient department, an independent practice, and a health center suite, so the premise is not unreasonable.

But site of care and acquisition channel are two different levers, and payers frequently pull them together. A health center infusion suite is often already the low-cost site of care. If cost is genuinely the objective, the health center should be winning that argument on the merits - in the contract, with its own cost-per-episode data in hand.

If your organization already delivers infusion at a lower total cost of care than the alternatives in your market, that is a payer contracting position, not just an internal talking point. Bring episode-level cost and outcome data to the table rather than arguing the principle.

State law varies significantly

A number of states have enacted laws limiting or prohibiting payer-mandated white bagging, and legislative activity in this area continues to move. The scope of those laws differs meaningfully - some restrict mandates outright, some require provider consent, some apply only to specific drug classes or settings. Whether a given state law reaches self-funded employer plans is a separate and contested question. Check your own state's current statutes and regulations, and involve counsel before you build policy on an assumption about what a mandate can or cannot require.

What white bagging does to 340B economics

This is where covered entities need to be precise. The 340B program lets eligible entities purchase covered outpatient drugs at a discounted price. The savings are generated at purchase. If the covered entity does not purchase the drug, there is no 340B transaction to generate savings from.

Under a white bagging arrangement, the drug is typically purchased and dispensed by the payer's specialty pharmacy, not by the covered entity. In that structure the drug generally does not run through the entity's 340B account and generally does not produce 340B savings. Brown bagging works the same way. Specifics depend on how the individual arrangement is actually built and on applicable HRSA guidance, so document how each of your arrangements works rather than assuming a single answer covers all of them.

The practical consequence for an FQHC is straightforward. Payer-mandated white bagging can erode the 340B savings that underwrite a health center's infusion program and, by extension, the services those savings support. That erosion does not show up as a denial or a line item. It shows up as a slow decline in program contribution that is easy to misdiagnose. Tracking channel mix by payer is the only reliable way to see it, and our 340B management work usually starts with that reconciliation. For more on how in-house infusion and 340B interact, see 340B infusions: care continuity and cost savings.

What to do before your next contract cycle

Know your channel mix. Report infusion volume by payer and by acquisition channel. Most organizations cannot produce this on demand, which means they cannot see a shift until margin has already moved.

Address the channel in payer contracting. Acquisition-channel requirements belong in contract language, not in a policy bulletin issued mid-term. Negotiate notice requirements, exceptions for clinical urgency and dose adjustment, and clarity on who bears the cost of wasted patient-specific product.

Build the operational case. Document your turnaround time, waste rate, and total cost per infusion episode. Payers respond to data about their own spend more readily than to arguments about yours.

Model the downside honestly. Run your infusion pro forma with a realistic share of volume moved to white bagging. If the program only works at full buy and bill, that is a fragility worth knowing about now rather than at renewal. A turnkey infusion model or a dedicated infusion TPA partner can absorb some of that operational variability, but neither substitutes for a clear-eyed forecast.

Frequently Asked Questions

What is buy and bill?: Buy and bill is the drug acquisition model in which a provider purchases a provider-administered medication through its own account, holds it in inventory, administers it to the patient, and bills the payer under the medical benefit for both the drug and its administration. The provider fronts the acquisition cost and carries the financial risk until the claim is paid.
What is white bagging?: White bagging is when a payer's contracted specialty pharmacy dispenses a patient-specific dose of a provider-administered drug and ships it directly to the provider's site for administration. The provider does not purchase or bill for the drug; it adjudicates under the pharmacy benefit, and the provider bills only the administration codes.
What is the difference between white bagging and brown bagging?: Both route the drug through a payer's specialty pharmacy under the pharmacy benefit rather than through provider purchasing. The difference is delivery. Under white bagging the specialty pharmacy ships the patient-specific dose to the provider's site. Under brown bagging it dispenses the drug to the patient, who transports it to the appointment. Brown bagging carries greater chain-of-custody and storage concerns because the product is outside professional control between dispense and administration.
Is white bagging allowed under 340B?: White bagging is not prohibited by the 340B statute, but it generally does not generate 340B savings. Savings under 340B arise when the covered entity purchases the drug at the 340B price. Under a typical white bagging arrangement the payer's specialty pharmacy purchases and dispenses the drug, so it does not run through the covered entity's 340B account. Specifics depend on how the individual arrangement is structured and on applicable HRSA guidance.
Can a payer require white bagging?: It depends on the payer, the plan type, and the state. A number of states have enacted laws limiting or prohibiting payer-mandated white bagging, and the scope of those laws differs by state. Whether a state law applies to self-funded employer plans is a separate question. Providers should review their current contract language and their own state's statutes, and involve counsel where the answer is unclear.
How does white bagging change infusion billing?: Under buy and bill, the provider submits a medical benefit claim for both the drug HCPCS code and the administration codes. Under white bagging, the drug is billed by the dispensing specialty pharmacy under the pharmacy benefit, and the provider bills only the administration codes. Drug revenue and drug margin move off the provider's claim entirely, while receiving, storage, and scheduling coordination work typically remain with the provider.

The channel is a strategic decision, not a billing detail

Buy and bill, white bagging, and brown bagging get discussed as billing mechanics. They are not. They determine who owns the drug, who carries the risk, who controls the product before it enters a patient, and - for covered entities - whether 340B economics exist at all.

Organizations that treat the acquisition channel as a payer-driven inevitability tend to learn too late what it cost them. Organizations that track channel mix, negotiate it deliberately, and can defend their site of care on data tend to keep more of the program intact.

Not sure how much of your infusion volume has already shifted?

We help health centers and specialty practices map acquisition channel by payer, quantify the 340B and margin impact, and build the contracting position to defend the program.

Request a discovery call

Buy and Bill vs. White Bagging vs. Brown Bagging: A Practical Guide for Health Centers